During the past decade, Palmetto Retina Center conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 15 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 7 clinical trials were completed. i.e. 63.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Palmetto Retina Center" #1 sponsor was "Jaeb Center for Health Research" with 13 trials, followed by "Genentech, Inc." with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Kodiak Sciences Inc" with 3 trials sponsored and "National Eye Institute (NEI)" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Palmetto Retina Center" #1 collaborator was "National Eye Institute (NEI)" with 15 trials as a collaborator, "Regeneron Pharmaceuticals" with 6 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "Pfizer" with 4 trials as a collaborator and "Allergan" with 3 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Palmetto Retina Center" are "Diabetic Macular Edema" (11 trials), "Diabetic Retinopathy" (8 trials), "Macular Degeneration" (7 trials), "Proliferative Diabetic Retinopathy" (4 trials) and "Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Palmetto Retina Center" in a lesser frequency.

Most popular intervention types in "Palmetto Retina Center" are "Drug" (41 trials), "Procedure" (10 trials), "Other" (6 trials), "Behavioral" (2 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept" (5 trials), "Sham Procedure" (5 trials), "KSI-301" (3 trials), "Ranibizumab" (3 trials) and "Sham" (3 trials). Other intervention names were less common.

The vast majority of trials in "Palmetto Retina Center" are 48 trials for "All" genders.

Currently, there are NaN active trials in "Palmetto Retina Center". undefined are not yet recruiting, 4 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Palmetto Retina Center, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Palmetto Retina Center, 6 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".